Video

Glaukos COO shares product updates, 2021 pipeline

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|GLAUCOMA 360

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.


See more Glaucoma 360 coverage

Related Videos
Related Content
Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks
February 21st 2025

Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/InsideCreativeHouse)
February 19th 2025

Alcon announces US launch of Voyager direct selective laser trabeculoplasty device

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

MediPrint Ophthalmics moves forward with LL-BMT1, sustained drug delivery contact lenses for glaucoma
February 15th 2025

MediPrint Ophthalmics moves forward with LL-BMT1, sustained drug delivery contact lenses for glaucoma

(Image credit: AdobeStock/flashmovie)
February 11th 2025

Retinoblastoma care goes digital: insights from two decades of teleophthalmology

© 2025 MJH Life Sciences

All rights reserved.